--- title: "Efzofitimod | PepTracker Pro" url: https://peptrackerpro.com/peptides/efzofitimod description: "A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Efzofitimod Medium Evidence A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease. Aliases ATYR1923 +3 more Evidence Medium Evidence Last Updated 2026-07-03 Reading Time 5 min ## What It Is Efzofitimod (development code ATYR1923; also called iMod.Fc) is a first-in-class immunomodulator built from a naturally occurring splice variant of human histidyl-tRNA synthetase (HARS). Aminoacyl-tRNA synthetases are best known for their housekeeping role in protein synthesis, but the immunomodulatory (iMod) domain released from HARS in inflamed tissue acts as a signaling molecule. Efzofitimod fuses that iMod domain to the Fc region of a human antibody (IgG1), which both stabilizes the molecule and extends its half-life. The fusion binds with high selectivity to neuropilin-2 (NRP2), a receptor that is strongly upregulated on myeloid immune cells (monocytes, macrophages and dendritic cells) at active sites of inflammation. By engaging NRP2, efzofitimod down-regulates pro-inflammatory receptors and cytokines and promotes resolution of inflammation, rather than broadly suppressing the immune system the way corticosteroids do. Its lead indication is pulmonary sarcoidosis — a form of interstitial lung disease (ILD) in which clusters of inflammatory cells (granulomas) accumulate in the lungs and other organs, and where chronic oral corticosteroids remain the mainstay of treatment despite substantial long-term toxicity. Developer aTyr Pharma advanced efzofitimod through a positive Phase 1b/2a study (published in CHEST) into the global Phase 3 EFZO-FIT trial, which randomized 268 patients across the United States, Europe, Japan and Brazil to intravenous efzofitimod 3 mg/kg, 5 mg/kg or placebo on top of a forced steroid taper. In topline results reported in September 2025, EFZO-FIT did not meet its primary endpoint — the reduction in mean daily oral corticosteroid dose at week 48 (2.79 mg for 5 mg/kg vs 3.52 mg for placebo; p=0.33) — but the 5 mg/kg dose showed consistent, pre-specified benefits on patient-reported outcomes (King's Sarcoidosis Questionnaire lung and general-health scores, Fatigue Assessment Scale), complete steroid withdrawal, and maintenance of lung function (forced vital capacity), with a safety profile in line with earlier studies. Following an FDA Type C meeting, aTyr announced plans to meet with the agency and to file a new investigational new drug (IND) application in 2026 for a further global Phase 3 study. Efzofitimod also holds FDA Fast Track and Orphan Drug designations for pulmonary sarcoidosis. It is an investigational, hospital-administered biologic-class peptide given by IV infusion — not an approved drug and not a self-experimentation 'research peptide.' Because it targets a novel resolution-of-inflammation pathway (NRP2) rather than a single cytokine, it is closely watched as a potential steroid-sparing option across interstitial lung diseases. Also known as: ATYR1923, ATYR-1923, iMod.Fc, efzofitimod alfa ## Regulatory Status Investigational — not approved; Phase 3 for pulmonary sarcoidosis; FDA Fast Track and Orphan Drug designations Efzofitimod (ATYR1923, aTyr Pharma) is an investigational intravenous immunomodulator with no marketing approval anywhere as of 2026. Its global Phase 3 EFZO-FIT study in pulmonary sarcoidosis (268 patients) reported topline results in September 2025: it missed its primary endpoint (reduction in daily oral corticosteroid dose at week 48) but showed benefit for the 5 mg/kg dose across several pre-specified secondary measures. The FDA granted efzofitimod Fast Track designation and Orphan Drug designation for pulmonary sarcoidosis. Following a Type C meeting with the FDA, aTyr Pharma stated it intends to file a new IND in 2026 to support an additional global Phase 3 trial. It is administered by intravenous infusion in a clinical setting and is not available as a compounding-pharmacy 'research peptide.' Effective: July 2026 View FDA Source (https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study) ## Why Researchers Study It Efzofitimod is studied as a first-in-class test of whether a tRNA-synthetase-derived immunomodulator can resolve, rather than merely suppress, tissue inflammation by engaging neuropilin-2 (NRP2) on myeloid cells. In pulmonary sarcoidosis and other interstitial lung diseases, patients depend on long-term oral corticosteroids that carry serious cumulative toxicity, so a targeted, steroid-sparing agent that preserves lung function and reduces symptom burden would fill a major gap. Researchers are also interested in the NRP2 resolution pathway as a platform that could extend to other ILDs and chronic inflammatory conditions, and in what the EFZO-FIT results say about endpoint design (steroid-taper vs patient-reported and lung-function outcomes) in rare inflammatory lung disease. ## Proposed Mechanisms - Derived from the immunomodulatory (iMod) domain of a human histidyl-tRNA synthetase (HARS) splice variant, fused to an antibody Fc region for stability and extended half-life - Binds selectively and with high affinity to neuropilin-2 (NRP2), a receptor upregulated on myeloid immune cells at active sites of inflammation - Down-regulates pro-inflammatory receptors and cytokine production in monocytes, macrophages and dendritic cells - Promotes active resolution of inflammation rather than broad immunosuppression, distinguishing it from corticosteroids - In preclinical ILD models (bleomycin, silicosis, sarcoidosis, hypersensitivity pneumonitis, systemic sclerosis and RA-ILD) reduced immune-cell infiltration, inflammation and fibrosis - In sarcoidosis patients, down-regulated inflammatory gene-expression pathways in peripheral immune cells and stabilized serum inflammatory biomarkers during steroid tapering - Administered as an intravenous infusion dosed by body weight (3 or 5 mg/kg in Phase 3) ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | RCT (human, Phase 3 — EFZO-FIT) | Pulmonary sarcoidosis — 268 adults, IV efzofitimod 3 mg/kg or 5 mg/kg vs placebo on a forced steroid taper, 48 weeks | Missed primary endpoint (mean daily oral corticosteroid dose at week 48: 2.79 mg for 5 mg/kg vs 3.52 mg placebo; p=0.3313); 5 mg/kg showed benefit on KSQ-Lung, KSQ-General Health, Fatigue Assessment Scale, complete steroid withdrawal and preserved FVC. Topline Sept 2025 | Source: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study | | RCT (human, Phase 1b/2a) | Pulmonary sarcoidosis — dose-ranging, IV efzofitimod vs placebo with steroid taper | Positive: dose-dependent trends toward reduced steroid use and improved lung function and symptoms; supported advancement to Phase 3. Published in CHEST | Source: https://pubmed.ncbi.nlm.nih.gov/37059508/ | | Mechanism / translational (Science Translational Medicine 2025) | HARS splice-variant therapeutic (HARSWHEP / iMod.Fc) targeting NRP2 across multiple lung-inflammation and fibrosis models | Demonstrated selective NRP2 binding and resolution of lung inflammation and fibrosis; clarified first-in-class immunomodulatory mechanism | Source: https://www.science.org/doi/10.1126/scitranslmed.adp4754 | | Regulatory designations / status | Pulmonary sarcoidosis, adults | FDA Fast Track and Orphan Drug designations; not yet approved. Following a 2026 FDA Type C meeting, aTyr plans a new IND and additional global Phase 3 study | Source: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-provides-regulatory-and-clinical-update-efzofitimod | ## Commonly Discussed Benefits Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support Researching Efzofitimod? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=efzofitimod) ## Safety & Cautions - Investigational and not approved for any use — its Phase 3 EFZO-FIT trial missed its primary (steroid-reduction) endpoint, so efficacy is not established - A hospital/clinic-administered intravenous biologic-class peptide given under specialist supervision — not a self-administered or self-experimentation 'research peptide' - Any vendor offering 'efzofitimod' or 'ATYR1923' as a research chemical is illegitimate; the molecule is a complex Fc-fusion produced only for clinical trials - As an immunomodulator, it could in principle affect infection risk; the full long-term safety profile is still being characterized - Benefit seen so far is on secondary and patient-reported outcomes at the 5 mg/kg dose, which require confirmation in a further Phase 3 trial before any conclusions - Indicated (investigationally) for pulmonary sarcoidosis specifically — use in other interstitial lung diseases remains exploratory ## Comparisons See how Efzofitimod compares to related peptides: Efzofitimod vs Ara-290: https://peptrackerpro.com/compare/efzofitimod-vs-ara-290 Efzofitimod vs Batoclimab: https://peptrackerpro.com/compare/efzofitimod-vs-batoclimab Efzofitimod vs Efgartigimod: https://peptrackerpro.com/compare/efzofitimod-vs-efgartigimod Efzofitimod vs KPV: https://peptrackerpro.com/compare/efzofitimod-vs-kpv Efzofitimod vs Nipocalimab: https://peptrackerpro.com/compare/efzofitimod-vs-nipocalimab Efzofitimod vs Pegcetacoplan: https://peptrackerpro.com/compare/efzofitimod-vs-pegcetacoplan Efzofitimod vs Rozanolixizumab: https://peptrackerpro.com/compare/efzofitimod-vs-rozanolixizumab Efzofitimod vs Thymosin Alpha-1: https://peptrackerpro.com/compare/efzofitimod-vs-thymosin-alpha-1 Efzofitimod vs VIP: https://peptrackerpro.com/compare/efzofitimod-vs-vip Efzofitimod vs Zilucoplan: https://peptrackerpro.com/compare/efzofitimod-vs-zilucoplan ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (Sept 2025) PubMed (https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study) 2. [2] A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis. Science Translational Medicine, 2025 PubMed (https://www.science.org/doi/10.1126/scitranslmed.adp4754) 3. [3] aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting PubMed (https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-provides-regulatory-and-clinical-update-efzofitimod) 4. [4] Efzofitimod Fails to Meet Primary End Point in Phase 3 Pulmonary Sarcoidosis Trial — HCPLive PubMed (https://www.hcplive.com/view/efzofitimod-fails-to-meet-primary-end-point-in-phase-3-pulmonary-sarcoidosis-trial) 5. [5] Efzofitimod — Pulmonary Fibrosis Foundation pipeline profile PubMed (https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center/pipeline/drug/other-interstitial-lung-disease/efzofitimod) ### Keep researching in the app - Log Efzofitimod to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=efzofitimod Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Ara-290 Medium Evidence A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions. Nerve Repair: https://peptrackerpro.com/benefits/nerve-repair Pain Relief: https://peptrackerpro.com/benefits/pain-relief Inflammation: https://peptrackerpro.com/benefits/inflammation Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/ara-290 \+ Compare: https://peptrackerpro.com/compare?select=ara-290 Track in App: https://app.peptrackerpro.com/?add=ara-290 ### Batoclimab High Evidence Batoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/batoclimab \+ Compare: https://peptrackerpro.com/compare?select=batoclimab Track in App: https://app.peptrackerpro.com/?add=batoclimab ### Efgartigimod High Evidence Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis. View Details: https://peptrackerpro.com/peptides/efgartigimod \+ Compare: https://peptrackerpro.com/compare?select=efgartigimod Track in App: https://app.peptrackerpro.com/?add=efgartigimod ### KPV Medium Evidence A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties. Inflammation: https://peptrackerpro.com/benefits/inflammation Gut Health: https://peptrackerpro.com/benefits/gut-health Skin: https://peptrackerpro.com/benefits/skin Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/kpv \+ Compare: https://peptrackerpro.com/compare?select=kpv Track in App: https://app.peptrackerpro.com/?add=kpv ### Nipocalimab High Evidence Nipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition. View Details: https://peptrackerpro.com/peptides/nipocalimab \+ Compare: https://peptrackerpro.com/compare?select=nipocalimab Track in App: https://app.peptrackerpro.com/?add=nipocalimab ### Pegcetacoplan High Evidence A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market. Immune Support: https://peptrackerpro.com/benefits/immune-support Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/pegcetacoplan \+ Compare: https://peptrackerpro.com/compare?select=pegcetacoplan Track in App: https://app.peptrackerpro.com/?add=pegcetacoplan ### Rozanolixizumab High Evidence Rozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024. View Details: https://peptrackerpro.com/peptides/rozanolixizumab \+ Compare: https://peptrackerpro.com/compare?select=rozanolixizumab Track in App: https://app.peptrackerpro.com/?add=rozanolixizumab ### Thymosin Alpha-1 High Evidence A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy. Immune Support: https://peptrackerpro.com/benefits/immune-support Longevity: https://peptrackerpro.com/benefits/longevity Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/thymosin-alpha-1 \+ Compare: https://peptrackerpro.com/compare?select=thymosin-alpha-1 Track in App: https://app.peptrackerpro.com/?add=thymosin-alpha-1 ### VIP Medium Evidence A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair. Nerve Repair: https://peptrackerpro.com/benefits/nerve-repair Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/vip \+ Compare: https://peptrackerpro.com/compare?select=vip Track in App: https://app.peptrackerpro.com/?add=vip ### Zilucoplan High Evidence A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function View Details: https://peptrackerpro.com/peptides/zilucoplan \+ Compare: https://peptrackerpro.com/compare?select=zilucoplan Track in App: https://app.peptrackerpro.com/?add=zilucoplan ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Efzofitimod", "description": "A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease.", "url": "https://peptrackerpro.com/peptides/efzofitimod", "lastReviewed": "2026-07-03", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Efzofitimod", "item": "https://peptrackerpro.com/peptides/efzofitimod" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching first-in-class immunomodulatory peptides and the neuropilin-2 (NRP2) resolution-of-inflammation pathway?", "acceptedAnswer": { "@type": "Answer", "text": "Efzofitimod is a research peptide studied in preclinical models. A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease." } }, { "@type": "Question", "name": "Patients and clinicians following pulmonary sarcoidosis and interstitial lung disease treatment options and steroid-sparing agents?", "acceptedAnswer": { "@type": "Answer", "text": "Efzofitimod is a research peptide studied in preclinical models. A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease." } }, { "@type": "Question", "name": "Those interested in tRNA-synthetase-derived therapeutics and Fc-fusion peptides beyond the metabolic and longevity classes?", "acceptedAnswer": { "@type": "Answer", "text": "Efzofitimod is a research peptide studied in preclinical models. A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease." } } ] } ] ```